TwitterLinkedin

Contact Us

  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Our Milestones
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical

          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistical Services
            • Toxicology Services
    • Clinical Development

          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistical Services

          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations

          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting

          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval

          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access

          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistical Services

          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting

          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance

          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access

          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services

          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management

          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems

          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management

          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise

          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services

          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Statistical Services
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > Blog > Page 5

Blog

Upcoming TGA Deadlines for Medicine Labelling and Product Information Reform

Upcoming TGA Deadlines for Medicine Labelling and Product Information Reform

18th May 2020

Notified Body Updates for MDD, MDRs, IVDD and IVDR

Notified Body Updates for MDD, MDRs, IVDD and IVDR

4th May 2020

TGA continues to lead the way in Prescription Medicine Transparency

TGA continues to lead the way in Prescription Medicine Transparency

22nd April 2020

Look out…the new CMI templates are finally here

Look out…the new CMI templates are finally here

21st April 2020

China restricts export of COVID-19 supplies to approved products only

China restricts export of COVID-19 supplies to approved products only

16th April 2020

Expedite! Emergency device regulatory approvals in a pandemic

Expedite! Emergency device regulatory approvals in a pandemic

2nd April 2020

Six uncomfortable regulatory truths in a pandemic

Six uncomfortable regulatory truths in a pandemic

25th March 2020

Getting Shorty – Meeting your obligations for Reporting Medicines Shortages in Australia

Getting Shorty – Meeting your obligations for Reporting Medicines Shortages in Australia

24th March 2020

Keeping the genie in the bottle – managing genetically modified organisms (GMOs) in Australia

Keeping the genie in the bottle – managing genetically modified organisms (GMOs) in Australia

26th February 2020

2019 US 510(k) Clearances Analysis and FDA’s target to receive innovative technologies first in 2020

2019 US 510(k) Clearances Analysis and FDA’s target to receive innovative technologies first in 2020

26th February 2020

Self-Inspection – how can you add value?

Self-Inspection – how can you add value?

22nd May 2018
12345
prevnext
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
  • Statistics and Data Science
  • MedTech Services
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
20 Sep

September 21, 2021 | 02:30 PM CET – Remediation and Preparations: a recap of current state and what is next for Medical Devices and In Vitro Diagnostics in Europe under MDR and IVDR 

Register now: https://go.pharmalex.com/l/484291/2021-08-23/2mf655 

#medicalDevices 
#invitrodiagnostics 
#MDR

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY

  • During the bid defense we felt that you worked well as team and are very dynamic. Preparation of such a complex dossier really needs to be done in such a way.

    Large Pharma, Germany
    VP Regulatory Affairs
PharmaLex
©2021 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.





    Select your state:

    .
    You can unsubscribe at any time at data.protection@pharmalex.com

    Click here to view our Privacy Policy.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for